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Background. Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI), is active against wild-type 
Human Immunodeficiency Virus (HIV)-1 and the most common NNRTI-resistant variants, and has a favorable and unique in vitro 
resistance profile.
Methods. DRIVE-AHEAD is a phase 3, double-blind, non-inferiority trial. Antiretroviral treatment–naive adults with ≥1000 
HIV-1 RNA copies/mL were randomized (1:1) to once-daily, fixed-dose DOR at 100 mg, lamivudine at 300 mg, and tenofovir diso-
proxil fumarate (TDF) at 300 mg (DOR/3TC/TDF) or to efavirenz at 600 mg, emtricitabine at 200 mg, and TDF at 300 mg (EFV/
FTC/TDF) for 96 weeks. The primary efficacy endpoint was the proportion of participants with <50 HIV-1 RNA copies/mL at week 
48 (Food and Drug Administration snapshot approach; non-inferiority margin 10%).
Results. Of the 734 participants randomized, 728 were treated (364 per group) and included in the analyses. At week 48, 84.3% 
(307/364) of DOR/3TC/TDF recipients and 80.8% (294/364) of EFV/FTC/TDF recipients achieved <50 HIV-1 RNA  copies/mL 
(difference 3.5%, 95% CI, -2.0, 9.0). DOR/3TC/TDF recipients had  significantly  lower rates of dizziness (8.8% vs 37.1%), sleep 
disorders/disturbances (12.1% vs 25.2%), and altered sensorium (4.4% vs 8.2%) than EFV/FTC/TDF recipients. Mean changes in 
fasting low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C)  were significantly 
different between DOR/3TC/TDF and EFV/FTC/TDF (−1.6 vs +8.7 mg/dL and −3.8 vs +13.3 mg/dL, respectively).
Conclusions. In HIV-1 treatment-naive adults, DOR/3TC/TDF demonstrated non-inferior efficacy to EFV/FTC/TDF at week 
48 and was well tolerated, with significantly fewer neuropsychiatric events and minimal changes in LDL-C and non–HDL-C com-
pared with EFV/FTC/TDF.
Clinical Trials Registration. NCT02403674
Keywords. doravirine; efavirenz; HIV-1; treatment-naive; randomized controlled trial.
 Human Immunodeficiency Virus (HIV)-1 infection has been 
successfully treated with a wide array of antiretroviral thera-
pies, which can vastly improve life expectancy and reduce the 
risk of HIV-1 transmission, but cannot eradicate the infection. 
Because lifelong treatment is required, safeguarding against 
toxicity and comorbidity is important. Adverse events that 
may lead to treatment discontinuation include neuropsychiat-
ric toxicities, skin rashes, gastrointestinal toxicities, abnormal 
serum lipid levels, abnormal  renal or bone parameters, and 
drug-drug interactions [1]. Therefore, new antiretroviral ther-
apies with fewer unwanted side effects are needed.
Doravirine (DOR), a novel non-nucleoside reverse-tran-
scriptase inhibitor (NNRTI) of HIV-1, is active in vitro 
against both wild-type virus and the most common NNRTI-
resistant variants at concentrations achieved with 100  mg 
once-daily (QD) dosing [2, 3] and has a favorable in vitro 
resistance profile that is unique among NNRTIs [4]. Because 
it is not a metabolic inducer or inhibitor [5], DOR is not a 
perpetrator of pharmacokinetic drug-drug interactions. No 
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clinically meaningful interactions were observed when DOR 
was co-administered with atorvastatin, an oral contraceptive, 
a magnesium-based antacid, or a proton-pump inhibitor in 
healthy volunteers [6–8]. As a substrate of cytochrome P450 
(CYP)3A4, exposure to DOR  is reduced in the presence of 
moderate or strong inducers of CYP3A4 [9]. DOR can be 
taken once daily without regard to food [10], and its bioa-
vailability is not affected by age, gender, or moderate hepatic 
impairment [11, 12].
In a phase 2b study in treatment-naive adults, DOR at 
100  mg QD with emtricitabine (FTC) and tenofovir diso-
proxil fumarate (TDF) demonstrated comparable efficacy to 
efavirenz with FTC/TDF and had a favorable safety profile, 
with lower rates of drug-related adverse events and central 
nervous system (CNS) events than efavirenz [13–15]. In the 
phase 3 DRIVE-FORWARD trial, DOR at 100 mg QD demon-
strated non-inferior efficacy and a superior lipid profile com-
pared with darunavir-ritonavir after 48 weeks of combination 
treatment with 2 nucleoside reverse-transcriptase inhibitors 
(NRTIs) [16].
DOR is in development as both a single-entity tablet and a 
combination tablet containing DOR at 100 mg, lamivudine at 
300  mg, and TDF at 300  mg (DOR/3TC/TDF; MK-1439A). 
This report presents the results of a Phase 3 trial comparing the 
combination tablet, DOR/3TC/TDF, to ATRIPLA (efavirenz at 
600 mg, FTC at 200 mg, and TDF at 300 mg; EFV/FTC/TDF) in 
adults with previously-untreated HIV-1 infections.
METHODS
Study Design
DRIVE-AHEAD (MK-1439A Protocol 021; NCT02403674) is 
a phase 3, randomized, double-blind, non-inferiority trial con-
ducted at 126 sites worldwide (see Supplementary Appendix) 
and in conformance with International Conference on 
Harmonisation, Good Clinical Practice Guidelines and applica-
ble statutes and regulations regarding the protection of human 
participants in biomedical research. The study protocol was 
approved by the Independent Ethics Committee for each study 
site, and all participants provided written informed consent 
before any study procedures were performed. The double-blind 
trial continued for 96 weeks; the data cutoff for this report 
(week 48) was 20 March 2017.
Men and women ≥18 years of age with plasma HIV-1 RNA of 
≥1000 copies/mL (within 45 days before study treatment) who 
were naive to antiretroviral therapy were eligible for the trial if 
they had no documented or known resistance to any of the study 
drugs (see Supplementary Appendix) and had calculated cre-
atinine clearance of ≥50 mL/min. Participants were randomly 
assigned (1:1) to either DOR/3TC/TDF (plus placebo for EFV/
FTC/TDF) or EFV/FTC/TDF (plus placebo for DOR/3TC/
TDF), stratified by screening HIV-1 RNA (either ≤ or >100 000 
copies/mL) and chronic hepatitis B and/or C co-infection 
(either yes or no). DOR/3TC/TDF (and matching placebo) 
were taken orally QD, without regard to food, at approximately 
the same time each day. EFV/FTC/TDF (and matching placebo) 
were taken orally QD, at bedtime, on an empty stomach. No 
dose modifications were permitted during the study.
Procedures/Measurements
Plasma HIV-1 RNA was measured at all study visits by the cen-
tral laboratory using the Abbott RealTime HIV-1 assay (lower 
limit of quantification [LLoQ] of 40 copies/mL). Protocol-
defined virologic failure (PDVF) consisted of virologic rebound 
(confirmed HIV-1 RNA of ≥50 copies/mL after initial response 
of HIV-1 RNA of <50 copies/mL at any time during the study) 
or non-response (either confirmed HIV-1 RNA of ≥200 copies/
mL at week 24 or 36 or confirmed HIV-1 RNA of ≥50 copies/
mL at week 48). In all cases, confirmation required 2 consecu-
tive measures of HIV-1 RNA at least 1 week apart. Participants 
who met PDVF criteria were discontinued from the study, 
regardless of their adherence to the study therapy.
Testing for viral resistance to the study drugs was per-
formed for participants with PDVF and for participants who 
discontinued the trial for any reason, if HIV-1 RNA was 
>400 copies/mL. Post-baseline genotypic viral resistance to 
DOR was defined as any of the following mutations in the RT 
gene: L100I, K101E, V106A, V106I, V106M, V108I, E138K, 
Y188L, G190A, G190S, H221Y, P225H, F227C, F227L, F227V, 
M230I, M230L, L234I, P236L, and Y318F. Post-baseline geno-
typic resistance to EFV, FTC, 3TC, and TDF was assessed by 
Monogram Biosciences, LabCorp Specialty Testing Group. 
Phenotypic viral resistance to EFV and the NRTIs was defined 
by Monogram based on the difference (fold change) between 
the half-maximal inhibitory concentration (IC50) values for a 
participant’s virus and wild-type virus. Since no threshold for 
defining phenotypic resistance to DOR has yet been clinically 
defined, a 2.5-fold change in IC50 versus wild-type virus was 
used as a broad assay-reproducibility threshold for potential 
phenotypic resistance to DOR.
Safety was monitored by adverse event (AE) reporting, treat-
ment-emergent abnormalities in laboratory tests, and physical 
examinations. AEs were assessed by the investigator for inten-
sity (mild, moderate, severe), seriousness, and relationship to 
study therapy. Laboratory values were graded according to the 
Division of AIDS (DAIDS) Criteria [17].
Statistical Analysis
The primary efficacy population was the full analysis set 
(FAS), which consisted of all randomized participants who 
received at least 1 dose of a study drug. The primary efficacy 
endpoint was the proportion of participants achieving HIV-1 
RNA of <50 copies/mL at week 48 using the Food and Drug 
Administration’s “snapshot” approach [18], which treats all 
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missing values as failures, regardless of the reason. The differ-
ence between treatment groups at each time point and the asso-
ciated 95% confidence intervals (CIs) were calculated using the 
stratum-adjusted Mantel-Haenszel method. The prespecified 
non-inferiority margin was -10% [18]. With 340 participants 
per treatment arm, the trial had 90% power to demonstrate that 
DOR/3TC/TDF is non-inferior to EFV/FTC/TDF on the pri-
mary endpoint, at the 1-sided 2.5% alpha-level, assuming a true 
response rate of 80% for both arms.
Secondary and exploratory efficacy endpoints included 
HIV-1 RNA of <40 copies/mL, HIV-1 RNA of <200 copies/mL 
(analyzed using the same approach as described for the pri-
mary endpoint), a change from baseline in CD4+ T-cell counts, 
development of viral drug resistance (as described above), and 
efficacy by subgroup. The treatment difference in change from 
baseline in CD4+ T-cell count was estimated using the observed 
failure (OF) approach, with baseline values carried forward for 
participants who discontinued due to lack of efficacy. To assess 
the consistency of the treatment effect, the between-group dif-
ference for the primary endpoint (with nominal, unadjusted 
95% CI) was calculated within subgroups based on demo-
graphic and prognostic factors, using the OF approach.
Safety analyses included all randomized participants who 
received at least 1 dose of a study medication. The primary 
safety endpoint was the proportion of participants with neu-
ropsychiatric AEs in 3 pre-specified categories (dizziness, sleep 
disorders/disturbances, and altered sensorium), which repre-
sent the neuropsychiatric events most commonly reported in 
the phase 2b study of doravirine [13, 14]. The proportion of 
participants with neuropsychiatric AEs in 2 additional cate-
gories (depression/suicide/self-injury and psychosis/psychotic 
disorders) was a secondary endpoint. All preferred terms from 
the Medical Dictionary for Regulatory Activities (version 19.1) 
that fall into these categories were grouped for statistical anal-
ysis. Treatment differences and 95% CIs were calculated using 
Miettinen and Nurminen’s method [19], with P values provided 
for dizziness, sleep disorders/disturbances, and altered senso-
rium only. The change from baseline in fasting lipid levels was 
a secondary safety endpoint and was analyzed using analysis of 
covariance (ANCOVA) models adjusted by baseline lipid level 
and treatment group; inferential testing for statistical signifi-
cance for between-treatment comparisons was pre-specified 
for low-density lipoprotein cholesterol (LDL-C) and non–
high-density lipoprotein cholesterol (HDL-C) only.
RESULTS
Of the 734 participants assigned to DOR/3TC/TDF (n = 368) 
or EFV/FTC/TDF (n = 366), 364 in each group received study 
therapy and were included in the analyses. Demographics and 
baseline characteristics were generally similar between the treat-
ment groups (Table 1). By week 48, 14% of the DOR/3TC/TDF 
group and 17% of the EFV/FTC/TDF group had discontinued 
study treatment, primarily due to lack of efficacy, adverse 
events, withdrawal of consent, and loss to follow-up (Figure 1).
Efficacy
DOR/3TC/TDF was non-inferior to EFV/FTC/TDF on the 
primary efficacy endpoint, with 84.3% (307/364) and 80.8% 
(294/364) of participants, respectively, achieving HIV-1 RNA of 
<50 copies/mL at week 48 (difference, 3.5%; 95% CI, -2.0, 9.0). 
Virologic response rates were similar between the treatment 
groups at each time point (Figure 2) and across all baseline prog-
nostic and demographic factors except age (see Supplementary 
Appendix), with response rates favoring EFV/FTC/TDF in 
participants ≤31 years old and DOR/3TC/TDF in those older 
than 31. Among participants with high baseline HIV-1 RNA 
(>100 000 copies/mL), 56/69 (81.2%) in the DOR/3TC/TDF 
group and 59/73 (80.8%) in the EFV/FTC/TDF group achieved 
HIV-1 RNA of <50 copies/mL at week 48.
Similar results were observed for the virologic endpoints of 
HIV-1 RNA of <40 copies/mL (83.8% for DOR/3TC/TDF vs 
79.7% for EFV/FTC/TDF; difference, 4.1%; 95% CI, -1.5, 9.7) 
and HIV-1 RNA of <200 copies/mL (Table 2). The mean change 
in CD4+ T-cell count from baseline to week 48 was similar in 
the DOR/3TC/TDF and EFV/FTC/TDF groups (198 vs 188 
cells/mm3; difference, 10.1; 95% CI, -16.1, 36.3).
Viral Drug Resistance
Only 22 participants (6.0%) in the DOR/3TC/TDF group and 
14 (3.8%) in the EFV/FTC/TDF group met the criteria for con-
firmed PDVF, which was viral rebound in most cases (16/22 
and 10/14, respectively). Participants with PDVF generally had 
low-level viremia at the time of failure. Among those with viral 
rebound, 10/16 in the DOR/3TC/TDF group and 4/10 in the 
EFV/FTC/TDF group had HIV-1 RNA between 50 and 200 
copies/mL at the viral failure confirmation visit.
Results from viral drug-resistance testing are available for 
13 DOR/3TC/TDF recipients and 10 EFV/FTC/TDF recipients 
who met PDVF criteria, and for 9 and 13, respectively, who 
discontinued early without PDVF (Table 3). In the DOR/3TC/
TDF group, isolates from 7 participants (6 with non-response; 
1 rebound) had mutations associated with DOR resistance: 6 
isolates had both genotypic and phenotypic resistance to DOR 
(conferred through V106 in 4 cases, in combination with other 
mutations such as F227C) and to EFV; and 1 isolate had a DOR-
associated resistance mutation (Y318Y/F), but no phenotypic 
resistance to DOR or EFV. Five of the 7 isolates also had geno-
typic resistance to 3TC.
In the EFV/FTC/TDF group, isolates from 12 participants (4 
with non-response, 5 rebound, and 3 early discontinuation) had 
mutations associated with EFV resistance: 11 isolates had both 
genotypic and phenotypic resistance to EFV (conferred through 
K103N in 10 and G190E in 1); and one isolate had genotypic 
resistance to EFV (G190E), but phenotypic testing failed. Two 
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isolates with EFV resistance did not retain phenotypic sensitiv-
ity to DOR: 1 had G190E and 1 had K103N/M230L. Five of the 
12 isolates also had genotypic resistance to FTC.
Safety
Overall rates of any AE, drug-related AE, and discontinuation 
due to an AE were lower in the DOR/3TC/TDF group com-
pared with the EFV/FTC/TDF group (Table 4). The most com-
mon reasons for discontinuation were rashes (10 EFV/FTC/
TDF, 0 DOR/3TC/TDF) and CNS-related events (9 EFV/FTC/
TDF, 4 DOR/3TC/TDF). The most common drug-related AEs 
for DOR/3TC/TDF and EFV/FTC/TDF were dizziness (7% vs 
32%, respectively), abnormal dreams (5% vs 9%), nausea (5% 
vs 7%), and rash (2% vs 9%). Among the most common AEs of 
any causality, the largest treatment differences were observed 
for dizziness, abnormal dreams, and rash (Table 4).
On the primary safety endpoint, the proportion of partici-
pants with pre-specified neuropsychiatric events by week 48 was 
significantly lower in the DOR/3TC/TDF group compared with 
the EFV/FTC/TDF group for the categories of dizziness (8.8% 
vs 37.1%, respectively; P ≤  .001), sleep disorders/disturbances 
(12.1% vs 25.2%; P  ≤  .001), and altered sensorium (4.4% vs 
8.2%; P =  .033). For the secondary categories, the proportion 
of participants with depression/suicide/self-injury or psychosis/
psychotic disorders was numerically lower for DOR/3TC/TDF 
than EFV/FTC/TDF (Figure 3). These neuropsychiatric events 
were mild in the majority of cases in each group (DOR/3TC/
TDF, 72%; EFV/FTC/TDF, 75%).
Figure  4 displays the mean change in fasting lipid lev-
els from baseline to week 48. For LDL-C and non–HDL-C, 
the treatment difference was statistically significant (1-sided 
P  <  .0001), with minimal changes (-1.6 and -3.8  mg/dL, 
respectively) in the DOR/3TC/TDF group versus mean 
increases (8.7 and 13.3 mg/dL, respectively) in the EFV/FTC/
TDF group. The mean change from baseline in the total cho-
lesterol/HDL-C ratio was -0.23 for DOR/3TC/TDF and -0.18 
for EFV/FTC/TDF (difference, -0.07; 95% CI, -0.21, 0.07). 
Lipid-lowering therapy was modified during the study by 
2.2% (8/364) of DOR/3TC/TDF recipients and 2.5% (9/364) 
of EFV/FTC/TDF recipients (difference, 0.3%; 95% CI, -2.7, 
2.1). The incidence of DAIDS grade 3–4 laboratory abnormal-
ities, including serum creatinine, was low and similar between 
Table 1. Demographic and Baseline Characteristics
DOR/3TC/TDF EFV/FTC/TDF Total
(N = 364) (N = 364) (N = 728)
Age (years), Median (range) 32.0 (18, 70) 30.0 (18, 69) 31.0 (18, 70)
Male, n (%) 305 (84%) 311 (85%) 616 (85%)
Race, n (%)
 White 177 (49%) 170 (47%) 347 (48%)
 Black or African American 67 (18%) 68 (19%) 135 (19%)
 Asian 59 (16%) 65 (18%) 124 (17%)
 Othera 61 (17%) 61 (17%) 122 (17%)
 Hispanic or Latino Ethnicity 126 (35%) 120 (33%) 246 (34%)
Region, n (%)
 Africa 37 (10%) 27 (7%) 64 (9%)
 Asia/Pacific 59 (16%) 62 (17%) 121 (17%)
 Europe 88 (24%) 94 (26%) 182 (25%)
 Latin America 89 (24%) 87 (24%) 176 (24%)
 North America 91 (25%) 94 (26%) 185 (25%)
CD4+ T-Cell Count
 Median (range), cells/mm3 414 (19, 1399) 388 (19, 1452) 397 (19, 1452)
 ≤200 cells/mm3, n (%) 44 (12%) 46 (13%) 90 (12%)
 >200 cells/mm3, n (%) 320 (88%) 318 (87%) 638 (88%)
Plasma HIV-1 RNA
 Median (range), log10 copies/mL 4.4 (2.4, 6.1) 4.5 (2.6, 6.4) 4.4 (2.4, 6.4)
 ≤100 000 copies/mL, n (%) 291 (80%) 282 (77%) 573 (79%)
 >100 000 copies/mL, n (%) 73 (20%) 82 (23%) 155 (21%)
History of AIDS, n (%) 46 (13%) 53 (15%) 99 (14%)
Hepatitis B and/or C,b n (%) 11 (3%) 9 (2%) 20 (3%)
HIV-1 Subtype B, n (%) 232 (64%) 253 (70%) 485 (67%)
Abbreviations: DOR/3TC/TDF, doravirine at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate at 300 mg; EFV/FTC/TDF, efavirenz at 600 mg, emtricitabine at 200 mg, and 
tenofovir disoproxil fumarate at 300 mg; HIV, human immunodeficiency virus; RNA, ribonucleic acid.
aOther race includes multiracial, American Indian, or Alaska Native.
bEvidence of hepatitis B surface antigen or hepatitis C virus RNA.
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the treatment groups (see Supplementary Appendix). Specific 
bone and renal parameters were not evaluated in this trial; 
however, fractures and drug-related renal AEs occurred in 
<1% of each treatment group.
DISCUSSION
This Phase 3 trial evaluated the efficacy and safety of DOR/3TC/
TDF compared to the widely-used regimen of EFV/FTC/TDF 
in treatment-naive HIV-1–infected adults. The efficacy of 
DOR/3TC/TDF was non-inferior to that of EFV/FTC/TDF at 
week 48 (84.3% vs 80.8%, respectively) and was similar across 
baseline characteristics of gender, race, baseline viral load, and 
viral subtype. In both treatment groups, the virologic response 
rate was lower among participants with baseline HIV-1 RNA 
of >100 000 copies/mL (81.2% for DOR/3TC/TDF; 80.8% for 
EFV/FTC/TDF) compared to those with baseline HIV-1 RNA 
of ≤100 000 copies/mL (90.6% and 91.1%, respectively). Lower 
response rates in participants with high baseline viral loads has 
been observed in other clinical trials and across various antiret-
roviral classes [20, 21]. Response rates based on HIV-1 RNA 
thresholds of <40 and <200 copies/mL were consistent with the 
primary endpoint, and there was no notable difference between 
treatment groups in the change from baseline in CD4+ T-cell 
counts at week 48.
Figure 1. Disposition of participants through week 48. Abbreviations: DOR/3TC/TDF, doravirine at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate at 
300 mg; EFV/FTC/TDF, efavirenz 600 at mg, emtricitabine at 200 mg, and tenofovir disoproxil fumarate at 300 mg. †The most common reasons for screen failure were a 
documented or known resistance to any study drug (n = 139) and plasma Human Immunodeficiency Virus–1 RNA of <1000 copies/mL at screening (n = 62). Of 992 participants 
screened, ~2.4% were excluded due to doravirine-associated mutations (Y188L and V106I) and ~4.0% were excluded due to efavirenz-associated mutations (Y188L, K103N, 
L100I, K101, V108I, G190, and Y181C). ‡In error, 1 participant was randomized who did not meet inclusion/exclusion criteria. §Lack of efficacy was determined by investigator 
assessment (not a specific HIV-1 RNA level).
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The virologic response rate in the EFV/FTC/TDF group 
(80.8%) was similar to rates reported for this regimen in previ-
ous clinical trials: 81% [21] and 81.6% [22]. In both trials, dis-
continuation due to AEs was more frequent in the EFV/FTC/
TDF group than in the comparator group (10% vs 2% and 8.7% 
vs 2.5%, respectively), which also occurred in our study (6.3% 
vs 2.7%). These discontinuations reduced the observed response 
rate by the Food and Drug Administration snapshot approach, 
which treats all missing data as failures. When missing data are 
excluded (using the observed failure approach), higher viro-
logic response rates were observed for both treatment groups 
(DOR/3TC/TDF, 88.7%; EFV/FTC/TDF, 88.8%).
Response rates were also influenced by the conserva-
tive definition of PDVF used in this study, which required 
discontinuation of participants with HIV-1 RNA of ≥50 cop-
ies/mL at week 48, as well as those who became suppressed but 
later had confirmed HIV-1 RNA of ≥50 copies/mL, regardless 
of time point. Some participants had re-suppressed between 
the virologic failure confirmation visit and the discontinuation 
visit, but were required to discontinue per protocol. Other par-
ticipants who were discontinued due to PDVF criteria but had 
very low-level viremia may have re-suppressed if they had con-
tinued on treatment.
Through 48 weeks of treatment, genotypic resistance to DOR 
developed in 7 participants in the DOR/3TC/TDF group (1.9% 
overall; 32% of those with resistance testing), and genotypic 
resistance to EFV developed in 12 participants in the EFV/FTC/
TDF group (3.3% overall; 52% of those with resistance testing). 
Table 2. Virologic Outcomes at Week 48
DOR/3TC/TDF (N = 364) EFV/FTC/TDF (N = 364)
Primary Analysis (FDA Snapshot Approach) n (%) n (%)
 HIV-1 RNA <50 copies/mL 307 (84.3) 294 (80.8)
 HIV-1 RNA ≥50 copies/mLa 39 (10.7) 37 (10.2)
 No virologic data in week 48 window 18 (4.9) 33 (9.1)
  Discontinued study due to AE or deathb 9 (2.5) 24 (6.6)
  Discontinued study for other reasonsc 9 (2.5) 8 (2.2)
  On study but missing data in window 0 (0.0) 1 (0.3)
Secondary and exploratory endpoints n/N (%) n/N (%)
 HIV-1 RNA <50 copies/mL (observed failure) 307/346 (88.7) 294/331 (88.8)
 HIV-1 RNA <40 copies/mL (FDA snapshot) 305/364 (83.8) 290/364 (79.7)
 HIV-1 RNA <200 copies/mL (FDA snapshot) 313/364 (86.0) 301/364 (82.7)
Abbreviations: AE, adverse event; DOR/3TC/TDF, doravirine at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate at 300 mg; EFV/FTC/TDF, efavirenz at 600 mg, emtricitabine 
at 200 mg, and tenofovir disoproxil fumarate at 300 mg; HIV, human immunodeficiency virus; FDA, Food and Drug Administration.
aIncludes participants who changed any component of background therapy before week 48, participants who discontinued study drug before week 48 for lack or loss of efficacy, and partic-
ipants with HIV-1 RNA of ≥50 copies/mL in the week 48 window (relative day 295–378).
bIncludes participants who discontinued because of adverse event (AE) or death at any time point from day 1 through the time window if this resulted in no virologic data on treatment 
during the specified window.
cOther reasons include: lost to follow-up, non-compliance with study drug, physician decision, pregnancy, protocol deviation, screen failure, withdrawal by participant.
Figure  2. Proportion of participants with Human Immunodeficiency Virus–1 RNA of <50 copies/mL over time (Food and Drug Administration snapshot approach). 
Abbreviations: CI, confidence interval; DOR/3TC/TDF, doravirine at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate at 300 mg; EFV/FTC/TDF, efavirenz at 
600 mg, emtricitabine at 200 mg, and tenofovir disoproxil fumarate at 300 mg.
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Table 3. Treatment-emergent Drug Resistance, Week 48
DOR/3TC/TDF (N = 364) EFV/FTC/TDF (N = 364)
PDVFa
Discontinued  
Without PDVF Total PDVFa
Discontinued  
Without PDVF Total
Number (%) of participants, n (%) 22 (6.0) 35 (9.6) 57 (15.7) 14 (3.8) 50 (13.7) 64 (17.6)
Genotype test reported, n (%) 13 (3.4) 9 (2.5) 22 (6.0) 10 (2.5) 13 (3.4) 23 (6.3)
Phenotype test reported, n (%) 13 (3.4) 9 (2.5) 22 (6.0) 9 (2.5) 12 (3.3) 21 (5.8)
Genotypic NNRTI resistance, n (%) 7 (1.9) 0 7 (1.9) 9 (2.5) 3 (0.8) 12 (3.3)
Phenotypic NNRTI resistance, n (%) 6 (1.6) 0 6 (1.6) 8 (2.2) 3 (0.8) 11 (3.0)
Genotypic NRTI resistance, n (%) 5 (1.4) 0 5 (1.4) 5 (1.4) 0 5 (1.4)
Phenotypic NRTI resistance, n (%) 5 (1.4) 0 5 (1.4) 4 (1.1) 0 4 (1.1)
Specific NNRTI resistance mutations 
detected
Y188L; Y318Y/F; V106I, F227C; V106V/I,  
H221H/Y, F227C; F227C; V106A,  
P225H, Y318Y/F; V106M/T, F227C/R
K103N; K103N, E138E/G; K103N; K103N; G190E; K103N; 
K103N, M230L; G190E; K103N, V108V/I, T369T/A/I/V; 
K103N; K103N; K101K/N, K103N, P225P/H
Specific NRTI resistance mutations 
detected
M41L, M184V; M184V; M184V; K65R; K65K/R, 
M184V
V118I, M184V; M184V; M184V; M184V, 
K219K/E; K65K/R, M184M/I
Abbreviations: DOR/3TC/TDF, doravirine at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate at 300 mg; EFV/FTC/TDF, efavirenz at 600 mg, emtricitabine at 200 mg, and 
tenofovir disoproxil fumarate at 300 mg; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PDVF, protocol-defined virologic failure.
aPDVF was defined as either confirmed HIV-1 RNA of ≥50 copies/mL after initial response of HIV-1 RNA of <50 copies/mL at any time during the study; confirmed HIV-1 RNA of ≥200 copies/
mL at week 24 or week 36; or confirmed HIV-1 RNA of ≥50 copies/mL at week 48.
Table 4. Summary of Clinical Adverse Events
DOR/3TC/TDF QD EFV/FTC/TDF QD Treatment Difference
(N = 364) (N = 364) % (95% CI)
Any AE 301 (83%) 330 (91%) -8.0 (-13.0, -3.1)
Drug-relateda AE 113 (31%) 229 (63%) -31.9 (-38.6, -24.8)
Serious AE 13 (4%) 21 (6%) -2.2 (-5.5, 0.9)
Drug-related serious AE 1 (<1%) 4 (1%) -0.8 (-2.5, 0.5)
Deathsb 1 (<1%) 3 (1%) -0.5 (-2.2, 0.8)
Discontinued due to AE 11 (3%) 24 (7%) -3.6 (-6.9, -0.5)
Discontinued due to drug-related AE 8 (2%) 21 (6%) -3.6 (-6.7, -0.8)
Neuropsychiatric AE (pre-specified) 86 (24%) 207 (57%) -33.2 (-39.8, -26.4)
Most common adverse events (incidence ≥5% in either treatment group)c
Gastrointestinal disorders 120 (33%) 136 (37%) -4.4 (-11.3, 2.5)
 Diarrhea 39 (11%) 49 (13%) -2.7 (-7.6, 2.0)
 Nausea 28 (8%) 39 (11%) -3.0 (-7.3, 1.2)
 Vomiting 15 (4%) 27 (7%) -3.3 (-6.9, 0.1)
General disorders 56 (15%) 53 (15%) 0.8 (-4.4, 6.1)
 Fatigue 21 (6%) 22 (6%) -0.3 (-3.8, 3.3)
Infections and infestations 183 (50%) 174 (48%) 2.5 (-4.8, 9.7)
 Nasopharyngitis 39 (11%) 31 (9%) 2.2 (-2.1, 6.6)
 Pharyngitis 20 (5%) 15 (4%) 1.4 (-1.8, 4.7)
 Upper respiratory tract infection 33 (9%) 23 (6%) 2.7 (-1.2, 6.8)
Nervous system disorders 95 (26%) 177 (49%) -22.5 (-29.3, -15.6)
 Dizziness 32 (9%) 135 (37%) -28.3 (-34.0, -22.5)
 Headache 47 (13%) 45 (12%) 0.5 (-4.3, 5.4)
 Somnolence 12 (3%) 27 (7%) -4.1 (-7.6, -0.9)
Psychiatric disorders 62 (17%) 122 (34%) -16.5 (-22.7, -10.2)
 Abnormal dreams 17 (5%) 42 (12%) -6.9 (-11.0, -3.0)
 Insomnia 19 (5%) 32 (9%) -3.6 (-7.4, 0.1)
Skin/subcutaneous tissue disorders 61 (17%) 95 (26%) -9.3 (-15.3, -3.4)
 Rash 17 (5%) 44 (12%) -7.4 (-11.6, -3.5)
Abbreviations: AE, adverse event; CI, confidence interval; DOR/3TC/TDF, doravirine at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate at 300 mg; EFV/FTC/TDF, efavirenz 
at 600 mg, emtricitabine at 200 mg, and tenofovir disoproxil fumarate at 300 mg; QD, once daily.
aDetermined by the investigator to be related to study therapy.
bNone of the deaths were considered related to study therapy.
cCategory totals included all adverse events in the category, regardless of incidence.
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The rate and pattern of resistance observed in the EFV/FTC/TDF 
group was consistent with previous reports [21–25]. Resistance 
to DOR was primarily conferred by a substitution in RT V106, 
in combination with 1 or more mutations, which is consistent 
with in vitro data showing that DOR has a unique mechanism 
of resistance requiring multiple mutations or base-pair changes 
[4]. In a recent report, the prevalence of doravirine-associated 
mutations was lower than other NNRTI mutations among 
treatment-naive patients in Europe [26]. With in vitro activity 
against commonly-transmitted NNRTI mutations, and multi-
ple mutations needed for resistance in most cases, doravirine is 
likely to be effective in the majority of treatment-naive patients 
with transmitted NNRTI resistance. However, the DRIVE-
AHEAD trial was not designed to address this question, since 
patients with NNRTI resistance were excluded.
DOR/3TC/TDF was generally well-tolerated, with fewer 
drug-related AEs and discontinuations due to AEs than EFV/
FTC/TDF. DOR/3TC/TDF exhibited favorable neuropsychi-
atric tolerability and was superior to EFV/FTC/TDF in the 
analysis of dizziness, sleep disorders/disturbances, and altered 
sensorium, showing lower event rates in each of these catego-
ries. The incidence of rashes was also lower in the DOR/3TC/
TDF group (5% vs 12% in the EFV/FTC/TDF group) and was 
similar to that reported previously for doravirine (7%) [16]. 
Figure 3. Proportion of participants with neuropsychiatric adverse events in pre-specified categories. Abbreviations: DOR/3TC/TDF, doravirine at 100 mg, lamivudine at 
300 mg, and tenofovir disoproxil fumarate at 300 mg; EFV/FTC/TDF, efavirenz at 600 mg, emtricitabine at 200 mg, and tenofovir disoproxil fumarate at 300 mg. *P < .001, 
†P = .033. aStatistical testing was not pre-specified for the secondary categories (depression and suicide/self-injury; psychosis and psychotic disorders).
Figure 4. Mean change in fasting lipid levels from baseline to week 48. Abbreviations: DOR/3TC/TDF, doravirine at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil 
fumarate at 300 mg; EFV/FTC/TDF, efavirenz at 600 mg, emtricitabine at 200 mg, and tenofovir disoproxil fumarate at 300 mg; HDL-C, high-density lipoprotein cholestoral; 
LDL-C, low-density lipoprotein cholestoral. *P < .0001. aStatistical testing was not pre-specified for cholesterol, triglycerides, or HDL-C.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/68/4/535/5088828 by M
edicinsk Bibliotek, Aalborg Sygehus SYD
 user on 05 February 2019
Efficacy and Safety of DOR/3TC/TDF • CID 2019:68 (15 February) • 543
Furthermore, no participants in the DOR/3TC/TDF group 
discontinued treatment due to rashes. DOR/3TC/TDF demon-
strated a favorable overall profile for plasma lipid levels, includ-
ing significant differences between treatment groups for LDL-C 
and non–HDL-C (minimal changes in the DOR/3TC/TDF 
group versus mean increases in the EFV/FTC/TDF group). 
A similar favorable lipid profile was observed for doravirine in 
the DRIVE-FORWARD trial [16].
Our study had several limitations. Participants took 2 pills 
per day (1 active drug and 1 placebo), which could be taken 
together or at different times; since some participants may have 
taken the study medications at different times, resulting in a 
twice-daily regimen, the effects of improved adherence with a 
1-pill, once-daily regimen [27] could not be fully captured in this 
trial. Although the response rates appeared similar across most 
subgroups, several of these groups were relatively small, such as 
women (15.4%), Blacks/African Americans (18.5%), and those 
with high baseline viral loads (>100 000 copies/mL, 21.3%), low 
CD4+ T-cell counts (≤200/mm3, 12.4%), or hepatitis B/C co-in-
fections (2.7%). The small difference in treatment responses 
by age (favoring EFV/FTC/TDF in younger participants and 
DOR/3TC/TDF in older participants) was not observed in the 
DRIVE-FORWARD trial [13] and may be due to chance, since 
no adjustment was made for multiple comparisons and the trial 
was not powered to detect statistically-significant differences 
within subgroups [28].
In summary, DOR/3TC/TDF demonstrated robust antiretro-
viral efficacy that was statistically non-inferior to that of EFV/
FTC/TDF, immunologic efficacy similar to that of EFV/FTC/
TDF, and a low rate of treatment-emergent viral drug resis-
tance. DOR/3TC/TDF was superior to EFV/FTC/TDF for neu-
ropsychiatric AEs and changes in LDL-C and non–HDL-C, 
and was associated with lower rates of rashes, drug-related AEs, 
and discontinuation due to AEs. The favorable safety profile of 
DOR/3TC/TDF may reduce the likelihood of non-compliance 
and treatment discontinuation. Overall, DOR/3TC/TDF is a 
promising new treatment option for adults with HIV-1 infections.
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